Congratulations to SECVBD Project 1 investigator Dr. Matt DeGennaro (pictured) who, in collaboration with Ginkgo Bioworks, Azitra, Inc., FIU, and Latham BioPharm Group (LBG), was awarded a $15M contract by the Defense Advanced Research Projects Agency (DARPA) as part of itsReVector program. The team plans to create a new type of mosquito repellent that is based on the skin microbiome. The new repellent, a Live Biotherapeutic Product (LBP), will block human chemical signals which mosquitoes are attracted to while also repelling the insects. This new mosquito repellent is expected to be applied to situations in military, consumer, and global health. Read more about this novel repellent here and here!